WO2004053098A3 - Base, a new cancer gene, and uses thereof - Google Patents

Base, a new cancer gene, and uses thereof Download PDF

Info

Publication number
WO2004053098A3
WO2004053098A3 PCT/US2003/039476 US0339476W WO2004053098A3 WO 2004053098 A3 WO2004053098 A3 WO 2004053098A3 US 0339476 W US0339476 W US 0339476W WO 2004053098 A3 WO2004053098 A3 WO 2004053098A3
Authority
WO
WIPO (PCT)
Prior art keywords
base
base2
proteins
antibodies
expressing
Prior art date
Application number
PCT/US2003/039476
Other languages
French (fr)
Other versions
WO2004053098A2 (en
Inventor
Ira H Pastan
Kristi A Egland
James J Vincent
Byungkook Lee
Robert Strausberg
Original Assignee
Human Services D By The Secret
Ira H Pastan
Kristi A Egland
James J Vincent
Byungkook Lee
Robert Strausberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Services D By The Secret, Ira H Pastan, Kristi A Egland, James J Vincent, Byungkook Lee, Robert Strausberg filed Critical Human Services D By The Secret
Priority to AU2003296508A priority Critical patent/AU2003296508A1/en
Publication of WO2004053098A2 publication Critical patent/WO2004053098A2/en
Publication of WO2004053098A3 publication Critical patent/WO2004053098A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to the discovery of a new gene, termed 'BASE,' which is expressed in some 25% of breast cancers and in salivary glands. BASE is expressed in two alternatively spliced forms: a 19.5 kD, 179 amino acid secreted protein called 'base1,' and a 8.4 CKD, 79 amino acid non-secreted protein called 'base2.' The invention provides antibodies to base l and to base2. Antibodies to the proteins can be used to detect the presence of base l or base2 in a sample, thereby detecting the presence of a BASE-expressing breast cancer. Antibodies to base2 attached to a therapeutic agent can direct the agent to base2-expressing cells. Base1 and base2, immunogenic fragments of the proteins, and analogs of the proteins can be used to raise immune responses to BASE-expressing cancer cells. The invention further provides uses for using the proteins in manufacturing medicaments and methods for using antibodies to the proteins, attached to therapeutic molecules, to inhibit the growth of cancer cells expressing BASE.
PCT/US2003/039476 2002-12-10 2003-12-10 Base, a new cancer gene, and uses thereof WO2004053098A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003296508A AU2003296508A1 (en) 2002-12-10 2003-12-10 Base, a new cancer gene, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43253102P 2002-12-10 2002-12-10
US60/432,531 2002-12-10

Publications (2)

Publication Number Publication Date
WO2004053098A2 WO2004053098A2 (en) 2004-06-24
WO2004053098A3 true WO2004053098A3 (en) 2006-01-26

Family

ID=32507949

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/039476 WO2004053098A2 (en) 2002-12-10 2003-12-10 Base, a new cancer gene, and uses thereof

Country Status (2)

Country Link
AU (1) AU2003296508A1 (en)
WO (1) WO2004053098A2 (en)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EGLAND K.A. ET AL: "Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins.", PROC NATL ACAD SCI USA., vol. 100, no. 3, 4 February 2003 (2003-02-04), pages 1099 - 1104, XP002308215 *
JIANG Y. ET AL: "Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays.", ONCOGENE., vol. 21, no. 14, March 2002 (2002-03-01), pages 2270 - 2282, XP001075060 *

Also Published As

Publication number Publication date
AU2003296508A8 (en) 2004-06-30
AU2003296508A1 (en) 2004-06-30
WO2004053098A2 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
BR0316435A (en) Genetic products differentially expressed in and use of tumors
WO1998031818A3 (en) Tace-like and matrilysin-like polypeptides
BRPI0411112A (en) heterologous fusion protein, polynucleotide, vector, host cell, process for producing a heterologous fusion protein, method for treating a patient, and use of heterologous fusion protein
WO2001053349A3 (en) Small cell lung cancer associated antigens and uses therefor
BR0207325A (en) Therapeutic methods for diseases associated with decreased aop-1 or aop-1 gene expression
GEP20105111B (en) Rage fusion proteins and methods of use
Etges Identification of a surface metalloproteinase on 13 species of Leishmania isolated from humans, Crithidia fasciculata, and Herpetomonas samuelpessoai
WO2004016736A3 (en) Nucleic acids and corresponding proteins entitled 202p5a5 useful in treatment and detection of cancer
DK1151102T3 (en) Glycosylated leptin preparations and related methods
EA200601946A2 (en) ANTIBODIES CONNECTING STEAP-1 PROTEINS AND THEIR DERIVATIVES
PL372849A1 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CY1111431T1 (en) METHODS OF PRACTICAL PLUMBING GROWTH FACTORS OF TYPE 1, METHOD OF PREPARATION AND THEIR APPLICATIONS
Koistinen et al. Purification of placental protein PP12 from human amniotic fluid and its comparison with PP12 from placenta by immunological, physicochemical and somatomedin-binding properties
HUP0002472A2 (en) Isolated dendritic cell membrane protein genes
DE60332993D1 (en) THE BIOMOLECULAR TRANSDUCTION MOTIVE MPH-1-BTM AND ITS USE
WO2000043493A8 (en) Metalloproteinase adam 22
WO2004098515A3 (en) Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
Suck et al. Purification and immunobiochemical characterization of folding variants of the recombinant major wasp allergen Ves v 5 (antigen 5)
EP0369816A3 (en) Monoclonal antibodies specific for human polymorphic epithelial mucin
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
WO2004067716A3 (en) Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
ATE473235T1 (en) THE BIOMOLECULE TRANSDUCTION MOTIF SIM-2-BTM AND ITS USE
WO2004053098A3 (en) Base, a new cancer gene, and uses thereof
CN102336828B (en) Multiple myeloma specific protein and its special detection kit
AR019864A1 (en) PROCESS TO PRODUCE THE ANTIGEN OF TOXOPLASMA SAG1 OR FRAGMENTS OF THE SAME; PROTEIN SAG1 OR FRAGMENTS OF THE SAME EXPRESSED IN SUCH PROCESS; VACCINE COMPOSITIONS THAT INCLUDE SUCH PROTEIN SAG1 OR FRAGMENTS OF THE SAME; USE OF SUCH PROTEIN FOR THE MANUFACTURE OF MEDICINES TO PREVENT

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP